Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Background γ-Aminobutyric acid sub-type A receptors (GABAARs) are the most prominent
inhibitory neurotransmitter receptors in the CNS. They are a family of ligand-gated ion …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Both the discovery of biomarkers of schizophrenia and the verification of biological
hypotheses of schizophrenia are an essential part of the process of understanding the …

Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

GABA A receptors are pentameric ligand-gated ion channels that mediate most fast
neuronal inhibition in the brain. In addition to their important physiological roles, they are …

Recent advances in genomics have revealed a wide spectrum of genetic variants
associated with neurodevelopmental disorders at an unprecedented scale. An increasing …

The predominant inhibitory neurotransmitter in the brain, γ-aminobutyric acid (GABA), acts at
ionotropic GABAA receptors to counterbalance excitation and regulate neuronal firing …

The etiology of psychiatric disorders remains largely unknown. The exploration of the
neurobiological mechanisms of mental illness helps improve diagnostic efficacy and …

Identifying genes whose expression is associated with schizophrenia (SCZ) risk by
transcriptome-wide association studies (TWAS) facilitates downstream experimental studies …